Efficacy, Safety and PK of Once‐Daily Oral Semaglutide 25 mg for Obesity With and Without Type 2 Diabetes in Comparison With Subcutaneous Semaglutide 2.4 mg: A Model‐Informed Drug Development Approach

Documenti analoghi

• Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model‐Informed Drug Development Approach
  di: Anders Strathe, et al.
  Pubblicazione: (2026)
• Oral Semaglutide 25 mg Versus Orforglipron 36 mg in Obesity: A Population‐Adjusted Indirect Treatment Comparison
  di: Wojciech Michalak, et al.
  Pubblicazione: (2026)
• Comment on ‘Efficacy, Safety and Pharmacokinetics of Semaglutide 1.7 mg for Obesity Treatment in Adolescents: A Model‐Informed Drug Development Approach’
  di: Vijay Kumar K. V., et al.
  Pubblicazione: (2026)
• Effect of semaglutide 2.4 mg on physical functioning and weight‐ and health‐related quality of life in adults with overweight or obesity: Patient‐reported outcomes from the STEP 1–4 trials
  di: Domenica Rubino, et al.
  Pubblicazione: (2024)
• SEMASEARCH Study Design: Real‐World Evaluation of Semaglutide 2.4 mg in Adults With Severe Obesity Underrepresented in Clinical Trials
  di: Pierre Bel Lassen, et al.
  Pubblicazione: (2026)